As the number of biosimilars in development keeps on growing, reaching nearly 700 products to date, demand for data from randomized controlled trials (RCTs) and an understanding of these new biologics is peaking the interest of many.
Lancet has reported the results of a randomized, double-blind, placebo-controlled trial of tocilizumab in patients with new-onset giant cell arteritis (GCA).
The frequency of not returning (lost to follow-up) (LTFU) in patients with rheumatic diseases is high. Associated demographic factors included older age in RA, female gender in SLE and Ps/PsA, and younger age in Ps/PsA, with various reasons for being LTFU.
A systematic review by Khouri examined the extent drugs are capable of inducing Raynaud's phenomenon (RP).
The UNCOVER-2 and UNCOVER-3 trials were presented at the American Academy of Dermatology (AAD) Annual Meeting taking this week in Washington, D.C.
Vitamin D supplementation for individuals with knee osteoarthritis and low 25-hydroxyvitamin D levels did not reduce knee pain or slow cartilage loss, according to a study appearing in the March 8 issue of JAMA.
Juvenile idiopathic arthritis (JIA) is clearly not related to rheumatoid arthritis and until recently has no identifiabile autoantigen linked to JIA.
Arkema and colleagues assessed maternal and fetal outcomes in patients with SLE, pre-clinical (prior to onset) SLE and prevalent maternal SLE during pregnancy compared with the general population.
Hip and knee intraarticular injection of corticosteroids are frequently prescribed to alleviate pain or inflammation in patients with osteoarthritis and rheumatoid arthritis, especially in the period leading up to scheduled arthroplasty.
Three million Americans are diagnosed with carpal tunnel syndrome each year.
Muscle weakness was independently associated with disability in patients with scleroderma, and as muscle weakness worsened, disability also increased, according to findings from a retrospective, nested, case control study.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
